Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory
agent, will improve the clinical condition of patients with rheumatoid arthritis who still
have active joint inflammation despite taking methotrexate for at least 6 months.